**Supplemental Digital Content 8. Linear-mixed effects model evaluating differences in the rate of LAZ change among HIV-exposed uninfected infants according to duration and type of ART exposure and maternal disease progression**

|  |  |  |  |
| --- | --- | --- | --- |
| **Exposures** | **LAZ at 6weeks**  | **LAZ change per month up to 3 months**  | **LAZ change per month from 3 to 12 months** |
| **Unadjusted mean difference (95%CI)**  | **Adjusted mean difference (95%CI)** |  **Unadjusted mean difference (95%CI)** |  **Adjusted mean difference (95%CI)** | **Unadjusted mean difference (95%CI)** | **Adjusted mean difference (95%CI)** |
| **Timing of ART exposure** |  |  |  |  |  |  |
| From conception  | 0.17(-0.28, 0.61) | -0.12(-0.63, 0.39) | -0.22(-0.43,- 0.02) | -0.23(-0.46, -0.01) | -0.03(-0.8, 0.03) | -0.04(-0.09, 0.01) |
| From early pregnancy  | 0.28(-0.35, 0.92) | 0.51(-0.18, 1.19) | -0.09(-0.38, 0.20) | -0.16(-0.47, 0.16) | -0.02(-0.09, 0.05) | -0.06(-0.13, 0.02) |
| From late pregnancy  | Reference  | Reference | Reference | Reference | Reference | Reference |
| **Type of ART**  |  |  |  |  |  |  |
| TDF-3TC-EFV/NVP | Reference | Reference | Reference | Reference | Reference | Reference |
| ZDV-3TC-EFV/NVP | 0.53(-0.20, 1.09) | 0.81(-0.20, 1.43) | -0.18(-0.43, 0.06) | -0.17(-0.44, 0.12) | -0.04(-0.10, 0.03) | -0.05(-0.12, 0.01) |
| PI-based ART | -0.53(-3.07, 2.00)  | -0.01(-2.57, 2.60)  | -0.59(-1.76, 0.58)  | -0.47(-1.66, 0.72)  | 0.03(-0.07, 0.65)  | 0.36(-0.00, 0.72)  |
| **Maternal disease progression**  |  |  |  |  |  |  |
| Early stage | Reference | Reference | Reference | Reference | Reference | Reference |
| Advanced stage | -0.29(-0.82, 0.24) | --0.43(-1.04, 0.19) | -0.19(-0.44, 0.06) | -0.28(-0.57, 0.00) | 0.00(-0.06, 0.06) | 0.08(0.01, 0.14) |

ART: antiretroviral therapy, TDF: tenofovir, ZDV: Zidovudine, 3TC: lamivudine, EFV: efavirenz, NVP: nevirapine, PI: protease inhibitor, LAZ: length-for-age z-score. CI: confidence interval.

Each model is adjusted for maternal age, education, BMI, parity, infants’ gender, and breastfeeding status. In addition the model the for duration of ART exposure was adjusted for type of ART and maternal disease progression and vice versa.